NO307498B1 - FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn - Google Patents
FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn Download PDFInfo
- Publication number
- NO307498B1 NO307498B1 NO920915A NO920915A NO307498B1 NO 307498 B1 NO307498 B1 NO 307498B1 NO 920915 A NO920915 A NO 920915A NO 920915 A NO920915 A NO 920915A NO 307498 B1 NO307498 B1 NO 307498B1
- Authority
- NO
- Norway
- Prior art keywords
- impotence
- erection
- preparation
- vip
- injection
- Prior art date
Links
- 201000001881 impotence Diseases 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 52
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims abstract description 43
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims abstract description 43
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims abstract description 43
- 229960001999 phentolamine Drugs 0.000 claims abstract description 21
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims abstract description 21
- 108090000189 Neuropeptides Proteins 0.000 claims abstract description 14
- 102000003797 Neuropeptides Human genes 0.000 claims abstract description 13
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001289 prazosin Drugs 0.000 claims abstract description 10
- 239000012266 salt solution Substances 0.000 claims description 5
- 108010084214 Peptide PHI Proteins 0.000 claims description 3
- 239000000132 Peptide PHI Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- YLBIOQUUAYXLJJ-WZUUGAJWSA-N peptide histidine methionine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 YLBIOQUUAYXLJJ-WZUUGAJWSA-N 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 35
- 230000001939 inductive effect Effects 0.000 abstract description 25
- 230000001272 neurogenic effect Effects 0.000 abstract description 24
- 230000001107 psychogenic effect Effects 0.000 abstract description 20
- 239000000674 adrenergic antagonist Substances 0.000 abstract description 19
- 239000007926 intracavernous injection Substances 0.000 abstract description 18
- 230000035515 penetration Effects 0.000 abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 abstract description 9
- GSYTVXOARWSQSV-BYPYZUCNSA-N L-methioninamide Chemical group CSCC[C@H](N)C(N)=O GSYTVXOARWSQSV-BYPYZUCNSA-N 0.000 abstract description 5
- 210000004899 c-terminal region Anatomy 0.000 abstract description 5
- 230000004936 stimulating effect Effects 0.000 abstract description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract description 4
- 101500027956 Homo sapiens Vasoactive intestinal peptide Proteins 0.000 abstract description 2
- 230000018052 penile erection Effects 0.000 abstract description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 54
- 230000000638 stimulation Effects 0.000 description 28
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 27
- 239000007924 injection Substances 0.000 description 27
- 238000002347 injection Methods 0.000 description 27
- 229960001789 papaverine Drugs 0.000 description 27
- 229940090044 injection Drugs 0.000 description 26
- 230000001568 sexual effect Effects 0.000 description 25
- 210000003899 penis Anatomy 0.000 description 22
- 208000010228 Erectile Dysfunction Diseases 0.000 description 13
- 210000001367 artery Anatomy 0.000 description 13
- 210000005226 corpus cavernosum Anatomy 0.000 description 11
- 230000004064 dysfunction Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000001856 erectile effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 201000011264 priapism Diseases 0.000 description 7
- 239000002160 alpha blocker Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 5
- 230000001623 arteriogenic effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 229940100746 papaverine injection Drugs 0.000 description 5
- 229960003418 phenoxybenzamine Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 206010052005 Psychogenic erectile dysfunction Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940124572 antihypotensive agent Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000005225 erectile tissue Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 2
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 1
- TUEJFGFQYKDAPM-UHFFFAOYSA-N 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol;hydron;chloride Chemical compound Cl.C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 TUEJFGFQYKDAPM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000023803 Hip injury Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000005501 benzalkonium group Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001904 diabetogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003056 phentolamine mesylate Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 208000000331 vasculogenic impotence Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Load-Engaging Elements For Cranes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Revetment (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/408,754 US5236904A (en) | 1989-09-18 | 1989-09-18 | Erection-inducing methods and compositions |
PCT/US1990/005237 WO1991004039A1 (en) | 1989-09-18 | 1990-09-14 | Erection-inducing methods and compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
NO920915D0 NO920915D0 (no) | 1992-03-09 |
NO920915L NO920915L (no) | 1992-03-09 |
NO307498B1 true NO307498B1 (no) | 2000-04-17 |
Family
ID=23617626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO920915A NO307498B1 (no) | 1989-09-18 | 1992-03-09 | FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn |
Country Status (24)
Country | Link |
---|---|
US (1) | US5236904A (ru) |
EP (1) | EP0493485B1 (ru) |
JP (1) | JP3149946B2 (ru) |
KR (1) | KR100230720B1 (ru) |
AT (1) | ATE210994T1 (ru) |
AU (1) | AU641184B2 (ru) |
BR (1) | BR9007662A (ru) |
CA (1) | CA2065270C (ru) |
CZ (1) | CZ280446B6 (ru) |
DE (1) | DE69033881T2 (ru) |
DK (1) | DK0493485T3 (ru) |
ES (1) | ES2170050T3 (ru) |
FI (1) | FI104231B1 (ru) |
GE (1) | GEP19981264B (ru) |
HK (1) | HK1011292A1 (ru) |
HU (1) | HU208088B (ru) |
IL (1) | IL95505A (ru) |
LT (1) | LT3544B (ru) |
LV (1) | LV10198B (ru) |
NO (1) | NO307498B1 (ru) |
RO (1) | RO116346B1 (ru) |
RU (1) | RU2098120C1 (ru) |
SK (1) | SK279489B6 (ru) |
WO (1) | WO1991004039A1 (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447912A (en) * | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
DE4117249C2 (de) * | 1991-05-27 | 1998-05-14 | Christian Dr Stief | Linsidomin zur Behandlung erektiler Dysfunktionen |
US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
US5482039A (en) * | 1994-03-25 | 1996-01-09 | Vivus, Inc. | Process for diagnosing erectile dysfunction, and related methods of treatment |
US5583144A (en) * | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US6323211B1 (en) | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US20030004170A1 (en) * | 1997-05-19 | 2003-01-02 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
US5947901A (en) | 1997-09-09 | 1999-09-07 | Redano; Richard T. | Method for hemodynamic stimulation and monitoring |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6011043A (en) * | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
US6482426B1 (en) | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
US6706682B2 (en) * | 1999-01-21 | 2004-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of vascular endothelial growth factor in the treatment of erectile dysfunction |
US6730065B1 (en) * | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
US6650943B1 (en) | 2000-04-07 | 2003-11-18 | Advanced Bionics Corporation | Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction |
AU2001259848B2 (en) * | 2000-05-12 | 2005-10-13 | Septodont Holding Sas | Local anesthetic methods and kits |
US20060211753A1 (en) * | 2000-11-03 | 2006-09-21 | Ocularis Pharma, Inc. | Method and composition which reduces stimulation of muscles which dilate the eye |
US6885895B1 (en) * | 2001-04-26 | 2005-04-26 | Advanced Bionics Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
AU2006222233B2 (en) * | 2005-03-07 | 2011-05-12 | Mondobiotech Ag | Formulation for aviptadil |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
EP3412300A1 (en) | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
EP2464370B1 (en) * | 2009-08-14 | 2017-03-29 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
EP2493434A1 (en) | 2009-10-30 | 2012-09-05 | Medispec Ltd | Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves |
CA2873553C (en) | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
GB201221046D0 (en) * | 2012-11-22 | 2013-01-09 | Mens Health Ltd | Method of diagnosis |
GB201221032D0 (en) * | 2012-11-22 | 2013-01-09 | Mens Health Ltd | Method of treatment |
ES2818824T3 (es) | 2014-05-08 | 2021-04-14 | Phasebio Pharmaceuticals Inc | Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística |
CA2976038A1 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
WO2019102310A1 (en) | 2017-11-24 | 2019-05-31 | Alaval (Pty) Ltd | Vip formulation for management of inflammatory conditions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3898329A (en) * | 1971-09-17 | 1975-08-05 | Sami I Said | Vasoactive intestinal peptide, composition and method |
DE3637157A1 (de) * | 1985-11-01 | 1987-05-21 | Byk Gulden Lomberg Chem Fab | Arzneimittel zur behandlung erektiler dysfunktionen |
JPS62246595A (ja) * | 1986-04-17 | 1987-10-27 | Eisai Co Ltd | 気菅支拡張作用・降圧作用ペプタイド |
US4939224A (en) * | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
IL87055A (en) * | 1988-07-08 | 1994-06-24 | Illana Gozes | Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them |
SE463851B (sv) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
-
1989
- 1989-09-18 US US07/408,754 patent/US5236904A/en not_active Expired - Lifetime
-
1990
- 1990-08-28 IL IL95505A patent/IL95505A/xx active IP Right Grant
- 1990-09-14 HU HU92874A patent/HU208088B/hu unknown
- 1990-09-14 CA CA002065270A patent/CA2065270C/en not_active Expired - Lifetime
- 1990-09-14 WO PCT/US1990/005237 patent/WO1991004039A1/en active IP Right Grant
- 1990-09-14 ES ES90914620T patent/ES2170050T3/es not_active Expired - Lifetime
- 1990-09-14 DE DE69033881T patent/DE69033881T2/de not_active Expired - Lifetime
- 1990-09-14 DK DK90914620T patent/DK0493485T3/da active
- 1990-09-14 AU AU64404/90A patent/AU641184B2/en not_active Expired
- 1990-09-14 AT AT90914620T patent/ATE210994T1/de not_active IP Right Cessation
- 1990-09-14 JP JP51377290A patent/JP3149946B2/ja not_active Expired - Lifetime
- 1990-09-14 EP EP90914620A patent/EP0493485B1/en not_active Expired - Lifetime
- 1990-09-14 BR BR909007662A patent/BR9007662A/pt not_active Application Discontinuation
- 1990-09-14 RU SU925011648A patent/RU2098120C1/ru active
- 1990-09-14 RO RO92-200339A patent/RO116346B1/ro unknown
- 1990-09-17 CZ CS904524A patent/CZ280446B6/cs not_active IP Right Cessation
- 1990-09-17 SK SK4524-90A patent/SK279489B6/sk not_active IP Right Cessation
-
1992
- 1992-03-09 NO NO920915A patent/NO307498B1/no not_active IP Right Cessation
- 1992-03-10 KR KR1019920700543A patent/KR100230720B1/ko not_active IP Right Cessation
- 1992-03-17 FI FI921136A patent/FI104231B1/fi active
-
1993
- 1993-06-29 LV LVP-93-740A patent/LV10198B/lv unknown
- 1993-08-25 GE GEAP19931497A patent/GEP19981264B/en unknown
- 1993-12-10 LT LTIP1579A patent/LT3544B/lt not_active IP Right Cessation
-
1998
- 1998-11-30 HK HK98112509A patent/HK1011292A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO307498B1 (no) | FremgangsmÕte for fremstilling av et preparat for behandling av impotens hos menn | |
US5447912A (en) | Erection-inducing methods and compositions | |
Rajfer et al. | Prevalence of corporeal venous leakage in impotent men | |
Lue | Impotence: a patient's goal-directed approach to treatment | |
Gerstenberg et al. | Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure | |
Earle et al. | Prostaglandin E1 therapy for impotence, comparison with papaverine | |
Nellans et al. | Pharmacological erection: diagnosis and treatment applications in 69 patients | |
WILLIAMS et al. | Diagnosis and treatment of venous leakage: a curable cause of impotence | |
Buvat et al. | Venous incompetence: critical study of the organic basis of high maintenance flow rates during artificial erection test | |
US6258373B1 (en) | Treatment of sexual dysfunction in certain patient groups | |
Kiely et al. | Assessment of the immediate and long‐term effects of pharmacologically induced penile erections in the treatment of psychogenic and organic impotence | |
US6110489A (en) | Use of quinolines and quinolones to treat male erectile dysfunction | |
Knispel et al. | Influence of cause on choice of therapy in 174 patients with erectile dysfunction | |
De Palma | New developments in the diagnosis and treatment of impotence. | |
Vickers et al. | The current cavernosometric criteria for corporovenous dysfunction are too strict | |
Wespes et al. | Impotence due to corporeal veno-occlusive dysfunction: long-term follow-up of venous surgery | |
US6132753A (en) | Treatment of sexual dysfunction in certain patient groups | |
US6303135B1 (en) | Use of quinolines and quinolones to treat male erectile dysfunction | |
Fouda et al. | Priapism: an avoidable complication of pharmacologically induced erection | |
Iacono et al. | Evaluation of penile deep arteries in psychogenic impotence by means of duplex ultrasonography | |
WO2002019997A1 (en) | Pde iii inhibitors for treating sexual dysfunction | |
Mooradian et al. | Biweekly intracavernous administration of papaverine for erectile dysfunction. | |
US6426084B1 (en) | Treatment of sexual dysfunction in certain patient groups | |
Parrott et al. | Penile vein dissection: a study of its long-term efficacy in impotence | |
Jantos et al. | Pharmacocavernosography in the evaluation of erectile failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |